

Baxter – Recall of ondansetron injection

- On November 21, 2023, [Baxter announced](#) a consumer-level recall of certain lots of [ondansetron injection](#) because the pH level parameter may be out of specification.
- These products were first distributed June 8, 2022.

Product Description	NDC Number	Lot Number (Exp Date)
Ondansetron injection 4 mg/2 mL	55154-4453-5	A0E0959AA (11/2023), A0E0961AA (11/2023), A0F0261AA (2/2024), A0F0262AA (2/2024), A0F0414AA (4/2024), A0F0417AA (4/2024), A0F0417AB (4/2024), A0F0418AA (4/2024), A0F0418AB (4/2024), A0F0535AA (6/2024), A0F0537AA (6/2024), A0F0574AA (7/2024), A0F0592AA (7/2024), A0F0599AA (8/2024)
	36000-012-25	A0E0865A (10/31/2023), A0E0959A (11/30/2023), A0E0961A (11/30/2023), A0E1015A (11/30/2023), A0E1020A (11/30/2023), A0E0016A (12/31/2023), A0F0260A (2/29/2024), A0F0261A (2/29/2024), A0F0262A (2/29/2024), A0F0414A (4/30/2024), A0F0415A (4/30/2024), A0F0416A (4/30/2024), A0F0417A (4/30/2024), A0F0418A (4/30/2024), A0F0503A (5/31/2024), A0F0533A (6/30/2024), A0F0534A (6/30/2024), A0F0535A (6/30/2024), A0F0536A (6/30/2024), A0F0537A (6/30/2024), A0F0540A (6/30/2024), A0F0541A (6/30/2024), A0F0573A (7/31/2024), A0F0574A (7/31/2024), A0F0575A (7/31/2024), A0F0592A (7/31/2024), A0F0596A (8/31/2024), A0F0599A (8/31/2024),

		A0F0676A (10/31/2024)
--	--	-----------------------

- Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat course of emetogenic cancer chemotherapy and for the prevention of postoperative nausea and/or vomiting.
- To date, Baxter has not received any reports of adverse events related to this recall.
- Anyone with the affected products on hand should stop distribution and return product. Consumers should contact their healthcare provider if they have experienced any problems that may be related to using this drug product.
- Consumers with questions regarding this recall can contact Baxter at 1-888-229-0001.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.